Oral Administration of Bioactive Nanoparticulates for Inflammatory Bowel Disease Therapy by Mitigating Oxidative Stress and Restoring Intestinal Microbiota Homeostasis
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Hong Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of High Talent, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Oxidative Stress, Nanoparticles, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shaanxi Provincial Science and Technology Department, First AffiliatedHospital of Xi?an Jiao tong University.
Abstract (Originalsprache)
The management of inflammatory bowel disease (IBD) continues to pose significant challenges due to the absence of curative therapies and a high rate of recurrence. Therefore, it is imperative to explore novel approaches to enhance the efficacy of IBD therapy. Herein, a bioactive nanoparticulate s is tailored designed to achieve a "Pull-Push" approach for efficient and safe IBD treatment by integrating reactive oxygen species (ROS) scavenging (Pull) with anti-inflammatory agent delivery (Push) in the inflammatory microenvironment. The multifunctional nanomedicine, designated MON-PAMAM@SASP, is developed through the encapsulation of sulfasalazine (SASP), a widely utilized clinical drug for the treatment of IBD, within cationic diselenide-bridged mesoporous organosilica nanoparticles (MONs) that possess significant antioxidant properties. Herein, poly(amidoamine) (PAMAM) endows the original MONs with positive charge characteristics. The MON-PAMAM@SASP not only displays the remarkable capability of neutralizing ROS to ameliorates intestinal damage, but also achieves controllable release of SASP to mitigate intestinal inflammation. Consequently, this nanomedicine effectively mitigates IBD by colitis in mouse models, and our current research has not identified any significant drug toxicity. Beyond regulating inflammatory microenvironment in intestine, treatment with MON-PAMAM@SASP results in increased richness and restores intestinal microbiota homeostasis, thereby mitigating IBD to a certain extent. Together, our work provides a highly versatile "Pull-Push" approach for IBD management and encourages the development of similar nanomedicine to treating multiple inflammatory diseases of gastrointestinal tract.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of High Talent, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
- Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
- The Third Department of General Surgery, Xi'an Daxing Hospital Affiliated to Yan'an University, Xi'an 710016, China.
- Department of Plastic and Aesthetic Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China.
- Center for Gut Microbiome Research, Med-X Institute, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi 710049, China.
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China.
ORCID-Profile: Fangman Chen, Yinnan Chen
Förderung
- National Natural Science Foundation of China
- Shaanxi Provincial Science and Technology Department
- First AffiliatedHospital of Xi?an Jiao tong University
- General Medical Research Project of Xi'an Science
- General Programs in Social Development
Zitieren
APA
Wu, H., Shi, C., Li, Q., Wang, L., Wang, R., Chen, F., Li, R., Guo, X., Chen, Y., & She, J. (2024). Oral Administration of Bioactive Nanoparticulates for Inflammatory Bowel Disease Therapy by Mitigating Oxidative Stress and Restoring Intestinal Microbiota Homeostasis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00499
Vancouver
Wu H, Shi C, Li Q, Wang L, Wang R, Chen F, et al. Oral Administration of Bioactive Nanoparticulates for Inflammatory Bowel Disease Therapy by Mitigating Oxidative Stress and Restoring Intestinal Microbiota Homeostasis. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00499
BibTeX
@article{Wu2024,
author = {Wu, Hong and Shi, Chengxin and Li, Qixin and Wang, Lizhao and Wang, Ruochen and Chen, Fangman and Li, Ruizhe and Guo, Xiaolong and Chen, Yinnan and She, Junjun},
title = {Oral Administration of Bioactive Nanoparticulates for Inflammatory Bowel Disease Therapy by Mitigating Oxidative Stress and Restoring Intestinal Microbiota Homeostasis},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00499}
}
EUVIMED